Abstract
Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.
| Original language | English |
|---|---|
| Pages (from-to) | 395-398 |
| Number of pages | 4 |
| Journal | International Congress Series |
| Volume | 1252 |
| Issue number | C |
| DOIs | |
| Publication status | Published - Jun 1 2003 |
Fingerprint
Keywords
- Alzheimer's disease
- Amyloid β
- Anti-amyloidogenic properties of melatonin
- Antioxidant properties of melatonin
- Melatonin
ASJC Scopus subject areas
- Medicine(all)
Cite this
Alzheimer's disease and melatonin. / Matsubara, Etsuro; Shoji, Mikio; Murakami, Tetsuro; Kawarabayashi, Takeshi; Abe, Koji.
In: International Congress Series, Vol. 1252, No. C, 01.06.2003, p. 395-398.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Alzheimer's disease and melatonin
AU - Matsubara, Etsuro
AU - Shoji, Mikio
AU - Murakami, Tetsuro
AU - Kawarabayashi, Takeshi
AU - Abe, Koji
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.
AB - Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.
KW - Alzheimer's disease
KW - Amyloid β
KW - Anti-amyloidogenic properties of melatonin
KW - Antioxidant properties of melatonin
KW - Melatonin
UR - http://www.scopus.com/inward/record.url?scp=4644249295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644249295&partnerID=8YFLogxK
U2 - 10.1016/S0531-5131(03)00019-0
DO - 10.1016/S0531-5131(03)00019-0
M3 - Article
AN - SCOPUS:4644249295
VL - 1252
SP - 395
EP - 398
JO - International Congress Series
JF - International Congress Series
SN - 0531-5131
IS - C
ER -